| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5687356 | The Journal of Urology | 2017 | 22 Pages |
Abstract
Metformin use during docetaxel chemotherapy did not significantly improve prostate cancer specific or overall survival in diabetic patients with metastatic castration resistant prostate cancer. This study indicates that metformin may not be an effective chemosensitizer for metastatic castration resistant prostate cancer.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Michelle J. Mayer, Laurence H. Klotz, Vasundara Venkateswaran,